Globenewswire·2025-10-06 11:30Core Insights - Context Therapeutics Inc. is advancing T cell engaging bispecific antibodies for solid tumors and will present two posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting in November 2025 [1][2] Presentation Details - The first poster is titled "Trial in Progress: A Phase 1, First-in-Human Study of CT-95, a mesothelin (MSLN)-Directed Bispecific T Cell engager (TCE) in Subjects with Advanced Solid Tumors," scheduled for November 8, 2025, at 10:00 AM ET [3] - The second poster is titled "CT-202: a dual pH-dependent Nectin-4 x CD3 bispecific T cell engager," scheduled for November 7, 2025, at 10:00 AM ET [3] Product Information - CT-95 targets mesothelin, a protein overexpressed in approximately 30% of cancers, and is designed to minimize the impact of shed MSLN that can interfere with treatment [4] - CT-202 targets Nectin-4, which is overexpressed in various solid tumors, and is designed to be preferentially active within the tumor microenvironment [5] Company Overview - Context Therapeutics is headquartered in Philadelphia and is focused on developing a portfolio of TCE bispecific therapeutics, including CTIM-76, CT-95, and CT-202 [6]